대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	A Case of New-Onset Stenotic Lesion After Using Drug-Coated Ballooning for Vascular Access Recurrent Stenosis
저자	Jin Ho Lee
출판정보	2026; 2026(1):
키워드	Hemodialysis Vascular access, recurrent stenosis, percutaneous transluminal angioplasty, drug-coated balloon
초록	Case Study: Drug-coated balloons (DCBs) are used to treat recurrent vascular access stenosis. Using DCBs in lesions requiring percutaneous transluminal angioplasty every 2-3 months can extend the patency interval, avoiding frequent procedures. However, we present a case in which stenosis occurred in a lesion completely different from the site of recurrent stenosis. The patient was a 56-year-old woman with end-stage renal disease (ESRD) who was on maintenance dialysis following Rt. Radiocephalic AVF surgery in 2020. The patient had recurrent stenosis in the venipuncture area every two months, and the stenosis was treated with an 8X40mm Mustang™ balloon. Recently, the IN.PACT™ Admiral™ DCB was approved for use in dialysis vessels in Korea, so we applied the DCB to our patient. Initially, the 8X40mm Mustang™ balloon was inflated, followed by an 8X40mm DCB balloon inflated for 3 minutes. The patient remained free of clinical indications for four months, and no stenosis was observed on ultrasound examination. Five months after DCB use, negative pressure was observed at the arterial puncture site. Ultrasound examination revealed normal findings in the recurrent stenotic lesion, but a new stenosis was observed at the juxta-anastomosis site. Treatment was completed with a 6x60mm Mustang™ balloon. DCB is an effective treatment tool for preventing neointimal growth in vascular access. As demonstrated in this case, stenotic lesions may develop in new locations instead of the stenotic areas previously treated with repeat percutaneous transluminal angioplasty (PTA). This lesion change is likely due to changes in intravascular hemodynamics. As DCB use increases, continuous monitoring will be necessary to maintain lesion patency and to monitor the development of new stenotic lesions.
원문(PDF)	PDF 원문보기

목록

위로가기